NurExone Biologic Inc. will ask shareholders on September 15, 2026, to approve a share consolidation of up to 30 pre-consolidation common shares for one post-consolidation share. If approved, the board could implement the consolidation at its discretion within 36 months, subject to TSXV (Canadian venture-stock exchange) acceptance and other required approvals. The final timing and ratio would depend on market conditions, trading performance and potential U.S. exchange requirements. The resolution requires at least 66⅔% of votes cast at the meeting. NurExone says the proposal is intended to support its broader capital-markets strategy and could help it meet minimum bid-price or similar requirements for a possible future major U.S. exchange listing. The company has made no final decision to pursue such a listing, file a registration statement with the SEC, conduct a financing or undertake another strategic transaction, and it cautions that the consolidation may not improve the share price, liquidity or marketability.